CT-322: Clinical Trials

3 trials of CT-322, newest first

ClinicalTrials Daily  ·  Areas  ·  Conditions  ·  Drugs  ·  Sponsors  ·  

1 completed, 1 terminated, 1 unknown. 3 Phase 2.

By phase and status

PhaseTrialsStatus
Phase 23Completed 1, Terminated 1, Unknown 1

Follow CT-322: new trials by email Literature Review of CT-322 trials Research Report on CT-322

Trials (filtered) newest first · largest first

All 3 trials

Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.

TrialPhaseStatusSponsorEnrollmentStartUpdated
Ph II Trial of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Second-line Treatment of Metastatic Colorectal Cancer
Irinotecan, 5-Fluorouracil (bolus), 5-Fluorouracil (infusional) - Colorectal Cancer (CRC)
Phase 2CompletedBristol-Myers Squibb172009-10-012015-10-12
Ph II of a Novel Anti-angiogenic Agent in Combination With Chemotherapy for the Treatment of Non-Small Cell Lung Cancer
Paclitaxel, Carboplatin, CT-322 - Non-small Cell Lung Cancer (NSCLC)
Phase 2TerminatedBristol-Myers Squibb2552009-06-012015-10-12
CT-322 in Treating Patients With Recurrent Glioblastoma Multiforme and Combination Therapy With Irinotecan
CT-322, irinotecan hydrochloride - Brain and Central Nervous System Tumors, Recurrent Glioblastoma Multiforme
Phase 2UnknownAdnexus, A Bristol-Myers Squibb R&D Company722007-10-012010-10-27

Conditions studied

Carcinoma, Non-Small-Cell Lung (1)  ·  Central Nervous System Neoplasms (1)  ·  Colorectal Neoplasms (1)  ·  Glioblastoma (1)

Sponsors

Bristol-Myers Squibb (2)  ·  Adnexus, A Bristol-Myers Squibb R&D Company (1)

Countries

United States (3)  ·  Italy (2)  ·  Argentina (1)  ·  Brazil (1)  ·  France (1)  ·  Poland (1)  ·  Russia (1)  ·  South Africa (1)  ·  United Kingdom (1)